Scholarly Activity - Infectious Diseases Fellowship

University of Maryland Infectious Diseases fellow in front of a research board

To set up a visiting rotation with the UMMC Infectious Diseases Program, email Tara Winterling.

Research is an important component of our Infectious Diseases fellowship training program.

There are immense research opportunities at the University of Maryland.

The University provides a fertile environment for research in the field of infectious diseases with the home of various institutes and centers (e.g., the Institute of Human Virology, the Institute of Global Health, the Center for Vaccine Development, the Institute of Genome Sciences, etc.)

All fellows are expected to participate in a research project as a component of their education.  Each fellow may choose a project that may be clinical, translational, or laboratory based. The choice is typically based on the fellow's individual career interests. Fellows meet with the program director or assistant program director in their first year to determine where their interests in the field of ID lie and are then referred to appropriate potential mentors as needed.

*Fellows are noted in bold*

Clinical Research

Toggle accordion item
  • Doll M, Preas MA, Johnson JK, Mitchell C, Roup B, Wilson L, Carothers C, Nkonge G, Leekha S. A pseudo-outbreak of aspergillosis at a tertiary care hospital: thinking beyond the infection control risk assessment. Infect Control Hosp Epidemiol. 2017;38(1):115-118.
  • Harris AD, Jackson SS, Robinson G, Pineles L, Leekha S, Thom KA, Wang Y, Doll M, Pettigrew MM, Johnson JK. Pseudomonas aeruginosa colonization in the intensive care unit: prevalence, risk factors, and clinical outcomes. Infect Control Hosp Epidemiol. 2016 May;37(5):544-8.
  • Heil EL, Bork JT, Schmalzle SA, Kleinberg M, Kewalramani A, Gilliam BL, Buchwald UK. Implementation of an Infectious Disease Fellow-Managed Penicillin Allergy Skin Testing Service. Open Forum Infect Dis. 2016;23;3(3):ofw155.
  • Harris AD, Jackson SS, Robinson G, Pineles L, Leekha S, Thom KA, Wang Y, Doll M, Pettigrew MM, Johnson JK. Pseudomonas aeruginosa colonization in the intensive care unit: prevalence, risk factors, and clinical outcomes. Infect Control Hosp Epidemiol. 2016;37(5):544-8.
  • Delva GJ, Francois I, Claassen CW, Dorestan D, Bastien B, Medina-Moreno S, Fort DS, Redfield RR, Buchwald UK. Active Tuberculosis Case Finding in Port-au-Prince, Haiti: Experiences, Results, and Implications for Tuberculosis Control Programs. Tuberc Res Treat. 2016;2016:8020745.
  • Croft L, Ladd J, Doll M, Morgan DJ. Inappropriate antibiotic use and gastric acid suppression preceding Clostridium difficile infection. Infect Control Hosp Epidemiol. 2016;37(4):494-5.
  • Riedel DJ, Cox ER, Stafford KA, Gilliam BL. Clinical presentation and outcomes of prostate cancer in an urban cohort of predominantly African-American, HIV-infected patients. Urology 2015;85(2):415-22.
  • Fisher LH, Stafford KA, Fantry LE, Gilliam BL, Riedel DJ. Cancer Knowledge and Opportunities for Education Among HIV-Infected Patients in an Urban Academic Medical Center. J Cancer Educ. 2015;30(2):319-26.
  • Gilliams EA, Jumare J, Claassen CW, Thesing PC, Nyirenda OM, Dzinjalamala FK, Taylor T, Plowe CV, Tracy LA, Laufer MK.  Chloroquine-azithromycin combination antimalarial treatment decreases risk of respiratory- and gastrointestinal-tract infections in Malawian children. J Infect Dis. 2014; 210:585-92. 
  • Osinusi-Adekanmbi O, Stafford K, Ukpaka A, Salami D, Ajayi S, Ndembi N, Abimiku A, Nwizu C, Gilliam B, Redfield R, Amoroso A. Long-term outcome of second-line antiretroviral therapy in resource-limited settings. J Int Assoc Provid AIDS Care. 2014;13:366-71.
  • Arnold R, Rock C, Croft L, Gilliam BL, Morgan DJ. Factors associated with treatment failure in vertebral osteomyelitis requiring spinal instrumentation. Antimicrob Agents Chemother. 2014 Feb;58(2):880-4.
  • Majid A, McAninch J, Morgan DJ, El Kamary SS, Zhan M, Kapelusznik L, Talwani R.  Predictors of early treatment discontinuation in a cohort of patients treated with boceprevir-based therapy for hepatitis C infection. J Viral Hepat. 2013;21(8):585-9.